Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2020 08:30 ET | Source: Fluidigm Corporation

ImmunoGenomics and Vero Diagnostics Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
September 15, 2020 08:30 ET | Source: Fluidigm Corporation

Fluidigm Announces Agenda for 9th Annual Mass Cytometry Summit

Virtual Event Showcases CyTOF Technology and Its Use in High-Parameter Suspension Mass Cytometry and Imaging Mass Cytometry Leading Academic and Pharma Researchers Detail Latest CyTOF Based...
September 08, 2020 08:30 ET | Source: Fluidigm Corporation

Fluidigm Achieves Initial Milestone under NIH Rapid Acceleration of Diagnostics Agreement

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
September 02, 2020 16:02 ET | Source: Fluidigm Corporation

Fluidigm to Participate at the 2020 Cantor Virtual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
August 25, 2020 23:00 ET | Source: Fluidigm Corporation

Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19

Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment Extraction-Free, Real-Time PCR Workflow with Capacity of up to 6,000 Tests per Day per System Demonstrated 100 Percent...
August 06, 2020 16:05 ET | Source: Fluidigm Corporation

Fluidigm Announces Second Quarter 2020 Financial Results

Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass...
August 04, 2020 08:30 ET | Source: Fluidigm Corporation

Fluidigm and De Novo Software to Offer Mass Cytometry Customers a Streamlined Solution for Data Analysis

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
July 31, 2020 11:10 ET | Source: Fluidigm Corporation

Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative

SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
July 20, 2020 08:30 ET | Source: Fluidigm Corporation

GnomeDX Files for FDA Emergency Use Authorization for Rapid Turnaround Real-Time RT-PCR COVID-19 Test Utilizing the Fluidigm Biomark HD Platform

Test Intended to Expand Availability of COVID-19 Screening Resources in Central Ohio Workflow with Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents Increasing Number of Labs...
July 06, 2020 16:02 ET | Source: Fluidigm Corporation

Fluidigm Announces Conference Call and Webcast of Second Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...